Challenges and Opportunities for Effective Cancer Immunotherapies

Anti-cancer immunotherapies have generated spectacular outcomes in the clinical environment and changed treatment schemes for cancer patients. Adoptive cell therapies (ACTs), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockad...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Formatua:	Online
Hizkuntza:	ingelesa
Argitaratua:	MDPI - Multidisciplinary Digital Publishing Institute 2023
Gaiak:	near infrared photoimmunotherapy monoclonal antibodies CD44 interleukin-15 cancer antigen processing and presentation cancer immunotherapy cross-priming immunogenicity major histocompatibility complex T lymphocyte tumor-infiltrating lymphocytes tumor microenvironment tumor-specific antigen pancreatic tumor NK cell immunosurveillance NKG2D histon (de)acetylation immunotherapy PD-1 microenvironment CAR T cells immune checkpoint inhibitors cervical cancer immune checkpoint inhibitor pembrolizumab recurrence pattern-recognition receptors toll-like receptors intratumoural tumour microenvironment NKG2D ligands NKG2D receptor NK cells immune evasion convergent evolution viruses glioblastoma model animal model preclinical murine immune response GBM newcastle disease virus modulated electrohyperthermia dendritic cell vaccination clinical trial individualized multimodal immunotherapy CAR-T cell therapy CD19 clinical trials CRS toxicity immunocyte membrane-coated nanoparticles biomimicry macrophage T-cell natural killer dendritic cell IL-12 family cytokines anti-tumor immunity STAT B cell T cell antibody therapy immuno-oncology CD3-bispecific antibody T-cell engager solid tumors on-target off-tumor toxicity T-cell co-stimulation tumor-associated antigens chimeric antigen receptor immune cell endodomain combination therapy TNFα adoptive cell therapy monoclonal antibody radiotherapy local ablation therapies checkpoint inhibitors chemotherapy protein kinase inhibitors oncolytic virus anti-cancer therapies T cell receptor chimeric antigen receptor (CAR) T cell (CAR-T) signal transduction CD8 coreceptor signaling kinetics oligomerization TAM receptors Axl MerTK small molecule inhibitors CAR T cell therapy T cell metabolism mitochondria memory T cell metabolic reprogramming adipose tissue-derived stem cells (ADSCs) mesenchymal stem cells myxoma virus oncolytic virotherapy pancreatic ductal adenocarcinoma Flt3 Flt3L dendritic cells HER2-positive breast cancer immune checkpoint blockade immune checkpoint molecules PD-1/PD-L1 melanoma tumour antigens Ropporin-1 ROPN1 Ropporin-1B ROPN1B nonreplicating adenovirus vector gene therapy routes of delivery virus coated with cancer cell membrane adoptive cell transfer targeted therapy cell cycle n/a thema EDItEUR::M Medicine and Nursing
Sarrera elektronikoa:	ONIX_20230405_9783036569604_226
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Deskribapena
Gaia:	Anti-cancer immunotherapies have generated spectacular outcomes in the clinical environment and changed treatment schemes for cancer patients. Adoptive cell therapies (ACTs), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockades have emerged as the most effective treatments for certain cancers. The current challenge for cancer immunotherapies is that although some patients have benefited from the treatments, a number of cancers are resistant. The purpose of this Special Issue is to understand anti-cancer immunotherapy treatment resistance mechanisms and explore new options to provide opportunities for effective treatments.

Challenges and Opportunities for Effective Cancer Immunotherapies

Antzeko izenburuak